YCG
BLTE

Yeomans Consulting Group’s Belite Bio BLTE Stock Holding History

Yeomans Consulting Group’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$384K Buy
+2,399
New +$284K 0.11% 82

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Yeomans Consulting Group's BLTE Position: Q4 2025 in Review

Yeomans Consulting Group opened a new position in Belite Bio (BLTE) in Q4 2025: 2,399 shares worth $384K. The stake represents 0.11% of the portfolio and ranks #82 among its holdings.

69 funds tracked by Wall St. Rank hold BLTE as of Q4 2025.

  • Yeomans Consulting Group held 2,399 shares of Belite Bio worth $384K as of Q4 2025.
  • Belite Bio was a new Yeomans Consulting Group position in Q4 2025.
  • Belite Bio made up 0.11% of Yeomans Consulting Group's portfolio in Q4 2025, its #82 holding.
  • 69 funds tracked by Wall St. Rank held Belite Bio as of Q4 2025.

Based on Yeomans Consulting Group's 13F filing for Q4 2025, filed 7 Jan 2026.